Method of detecting ionizing radiation using rare-earth orthophosphate, borate, aluminate, or hafnate scintillators

This patent covers a use-method for detecting ionizing radiation — gamma rays, X-rays, charged particles, and neutrons — using a defined set of rare-earth and hafnate scintillator host families: orthophosphates, borates, aluminates, and hafnates/tantalates/oxyfluorides, with or without activator dopants. The claimed act is exposing a host drawn from any of these genera to ionizing radiation and collecting the resulting luminescence. That framing is deliberate: because individual host compositions within these families appear in prior literature, anchoring the claim to the detection use — while tying it specifically to the disclosed genera — is what keeps the claim both novel and broad. Several host compositions are known; no one has claimed the detection method across this particular combination of four chemically distinct genera. The strategic value is leverage across the entire scintillator portfolio. A single method claim that spans four host families reaches every downstream application where any recited-genus material is used as a scintillator element. That makes this the connective tissue of the portfolio: even where a bare-composition claim on an individual host might face prior-art pressure, the method claim survives and remains enforceable. Securing it early anchors every genus-specific composition claim and every detector-device claim to a common, hard-to-design-around endpoint — radiation-induced luminescence from a disclosed-genus host. The urgency is not a competitive race to market; it is a filing-architecture imperative to lock in the method spine before the individual composition filings proliferate.

The four host genera covered — rare-earth orthophosphates, borates, aluminates (including aluminate perovskites), and hafnates (together with tantalates and oxyfluorides) — share the physical prerequisites for practical scintillation: high density for gamma and X-ray attenuation, wide bandgap to support efficient luminescence from activator or self-activated transitions, and dynamic stability sufficient to survive synthesis and operational thermal cycling. The underlying scintillation physics is well-established: an ionizing event deposits energy in the host lattice, electron-hole pairs thermalize and migrate to activator sites (or to intrinsic emission centers in self-activated hosts), and radiative recombination produces detectable luminescence that a photodetector converts to a signal. What is disclosed here is a specific and bounded set of host genera — not scintillation in general — and the method of using members of those genera for detection. Stability, density, and bandgap evidence for the recited host genera was generated through Lattice Graph's standard computational pipeline: candidate structures are evaluated by multiple independent machine-learning interatomic potentials (including MACE and CHGNet) and advanced to density-functional theory calculations only when those independent ML engines reach consensus on dynamic stability — meaning no imaginary phonon modes under any of the potentials. Structural and property data from those simulations underpin the host-genus characterization in the disclosure. Because this is a method claim rather than a new material, the cross-potential phonon stability consensus applies to the underlying hosts, not to the method itself; there is no independent phonon verdict for the claim as a whole. The breadth of the claim follows directly from the genus breadth: any host drawn from the recited families, whether doped with a rare-earth activator or operated in self-activated mode, used as the energy-absorbing and light-emitting element in a detector, falls within scope. That covers the full range of commercially relevant configurations — crystal, ceramic, or thin-film formats — across all four ionizing-radiation modalities listed.

The global scintillator and radiation-detector market is estimated at $1–5 billion addressable, spanning medical imaging (PET, CT, SPECT), security screening (cargo and passenger X-ray), high-energy physics instrumentation, industrial well-logging, and nuclear monitoring. These are distinct end markets with distinct procurement channels, but they share the same underlying physics: a scintillator crystal or ceramic coupled to a photodetector. A use-method claim that reaches the act of detecting ionizing radiation with a recited-genus host can be licensed across every one of these applications, independently of which specific host compound a customer selects from within the covered genera. The royalty logic here is structurally stronger than for a single-composition patent. A method claim can be asserted at the detector-module or complete-system level, supporting per-unit running royalties on detector subassemblies or field-of-use licenses scoped by application segment. A medical-imaging OEM, a security-screening integrator, and a well-logging service company could each hold independent field-of-use licenses under the same claim, with royalty rates reflecting the economics of their respective markets. This also means the addressable royalty base is broader than a naive reading of the host-genus composition claims alone: even an OEM that believed a particular host was free to use under prior art must contend with the method claim if that host falls within a disclosed genus. Customers are detector OEMs and imaging-system integrators — the companies that specify scintillator materials, qualify them into production processes, and embed them in end products sold to hospitals, airports, physics laboratories, and oil-and-gas operators. These buyers have strong incentives to take broad licenses covering all genera rather than per-composition licenses, because their product lines span multiple scintillator formulations and they want certainty across their portfolio of qualified materials.

use-claim moat spanning all four host genera; survives the individually-known-host limitation

method-of-detecting-radiation anchored to recited host genera; avoids bare-composition prior art

The most natural acquirers or licensees are diversified detector OEMs that build products across multiple radiation-detection modalities — medical imaging, security, physics, well-logging — and want a single license covering their use of any recited-genus host across their full product line. For such a buyer, a broad method license is more valuable than a composition license on a single host, because it provides certainty across the entire qualified-materials portfolio. Companies that already manufacture and sell scintillator-based detector modules in two or more of the named application segments fit this profile directly. Imaging-system integrators — particularly those developing next-generation CT or PET platforms where scintillator performance is a key differentiator — are a second buyer tier. For these companies the acquisition or exclusive license of the method claim converts a scintillator material decision into a protected platform position. Field-of-use licensing is also well-suited here: a medical-imaging acquirer could hold an exclusive license in the medical-imaging field while the method is simultaneously licensed non-exclusively to security or well-logging customers, maximizing total royalty capture. An acquirer of the full scintillator portfolio would value this claim as the keystone that makes the individual genus and device claims jointly enforceable across applications.

The method claim's strength depends entirely on the genus anchoring holding up under scrutiny. The claim was designed around the fact that several host compositions are individually known; if an examiner or inter partes challenger argues that detecting radiation with any host in a broadly defined inorganic family is anticipated by prior radiation-detection practice, the defense rests on how specifically and how distinctively the four genera are defined and characterized in the disclosure. Loose genus definitions would be fatal; tightly characterized, computationally supported genus boundaries are the asset's primary defensive structure. Enablement across four genera and all four radiation modalities is a related risk — the disclosure must demonstrably teach practitioners how to practice the method across the full claimed breadth, not just for one representative host. The absence of measured scintillation data is the most immediate practical risk: utility for a radiation-detection method is ultimately empirical, and an examiner may require experimental demonstration. This is also the most tractable risk to close. A single laboratory measurement on the lead orthophosphate host — run through a standard scintillator characterization protocol (light yield in photons per MeV, decay time, energy resolution at 662 keV) — provides the empirical anchor that resolves the utility question for the method, the device claim, and the leading composition claim simultaneously. That experiment is the highest-leverage single investment in the portfolio's near-term de-risking roadmap.